Exenatide as a potential treatment for patients with Parkinson's disease: First steps into the clinic

Alzheimer's and Dementia

Volumn 10, Issue 1 SUPPL., 2014, Pages

  Foltynie, Thomas ^a   Aviles Olmos, Iciar ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Clinical trial design; Exenatide; Exendin 4; GLP 1; Parkinson's disease

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; BLOOD BRAIN BARRIER; CLINICAL TRIAL (TOPIC); DISEASE SEVERITY; GENE EXPRESSION; HUMAN; MITOCHONDRIAL GENE; NERVE DEGENERATION; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OPEN STUDY; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; UNIFIED PARKINSON DISEASE RATING SCALE;

CLINICAL TRIAL DESIGN; EXENATIDE; EXENDIN 4; GLP-1; PARKINSON'S DISEASE;

DISEASE PROGRESSION; HUMANS; HYPOGLYCEMIC AGENTS; PARKINSON DISEASE; PEPTIDES; VENOMS;

EID: 84897848264     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2013.12.005     Document Type: Review

References (64)

1. T. Foltynie, C.E. Brayne, T.W. Robbins, and R.A. Barker The cognitive ability of an incident cohort of Parkinson's patients in the UK: the CamPaIGN study Brain 127 2004 550 560
2. A Schrag, and N Quinn Dyskinesias and motor fluctuations in Parkinson's disease: a community-based study Brain 123 2000 2297 2305
3. C.W. Olanow, K. Kieburtz, and A.H. Schapira Why have we failed to achieve neuroprotection in Parkinson's disease? Ann Neurol 64 2008 S101 S110
4. D.J. Drucker, and M.A. Nauck The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Lancet 368 2006 1696 1705
5. E.C. Hirsch, P. Jenner, and S. Przedborski Pathogenesis of Parkinson's disease Mov Disord 28 2013 24 30
6. K. Vekrellis, M. Xilouri, E. Emmanouilidou, H.J. Rideout, and L. Stefanis Pathological roles of alpha-synuclein in neurological disorders Lancet Neurol 10 2011 1015 1025
7. M. Mogi, A. Togari, T. Kondo, Y. Mizuno, O. Komure, and S. Kuno et al. Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease Neurosci Lett 270 1999 45 48
8. M. Mogi, A. Togari, T. Kondo, Y. Mizuno, O. Kogure, and S. Kuno et al. Glial cell line-derived neurotrophic factor in the substantia nigra from control and parkinsonian brains Neurosci Lett 300 2001 179 181
9. S.B. Rangasamy, K. Soderstrom, R.A. Bakay, and J.H. Kordower Neurotrophic factor therapy for Parkinson's disease Prog Brain Res 184 2010 237 264
10. T. Perry, D.K. Lahiri, D. Chen, J. Zhou, K.T. Shaw, and J.M. Egan et al. A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells J Pharmacol Exp Ther 300 2002 958 966
11. T. Perry, N.J. Haughey, M.P. Mattson, J.M. Egan, and N.H. Greig Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4 J Pharmacol Exp Ther 302 2002 881 888
12. M.G. Tansey, T.C. Frank-Cannon, M.K. McCoy, J.K. Lee, T.N. Martinez, and F.E. McAlpine et al. Neuroinflammation in Parkinson's disease: is there sufficient evidence for mechanism-based interventional therapy? Front Biosci 13 2008 709 713
13. X. Gao, H. Chen, M.A. Schwarzschild, and A. Ascherio Use of ibuprofen and risk of Parkinson disease Neurology 76 2011 863 869
14. International Parkinson's Disease Genetics Consortium A two-stage meta-analysis identifies several new loci for Parkinson's disease PLoS Genet 7 2011 e1002142
15. A Gerhard, N Pavese, G Hotton, F Turkheimer, M Es, and A Hammers et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease Neurobiol Dis 21 2006 404 412
16. J.K. Lee, T. Tran, and M.G. Tansey Neuroinflammation in Parkinson's disease J Neuroimmune Pharmacol 4 2009 419 429
17. S. Kim, M. Moon, and S. Park Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease J Endocrinol 202 2009 431 439
18. D. Shiraishi, Y. Fujiwara, Y. Komohara, H. Mizuta, and M. Takeya Glucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation Biochem Biophys Res Commun 425 2012 304 308
19. J.W. Langston, P. Ballard, J.W. Tetrud, and I. Irwin Chronic parkinsonism in humans due to a product of meperidine-analog synthesis Science 219 1983 979 980
20. A.Y. Abramov, M. Gegg, A. Grunewald, N.W. Wood, C. Klein, and A.H. Schapira Bioenergetic consequences of PINK1 mutations in Parkinson disease PLoS One 6 2011 e25622
21. L. Zhang, M. Shimoji, B. Thomas, D.J. Moore, S.W. Yu, and N.I. Marupudi et al. Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis Hum Mol Genet 14 2005 2063 2073
22. M. Muftuoglu, B. Elibol, O. Dalmizrak, A. Ercan, G. Kulaksiz, and H. Ogus et al. Mitochondrial complex I and IV activities in leukocytes from patients with parkin mutations Mov Disord 19 2004 544 548
23. R. Fan, X. Li, X. Gu, J.C. Chan, and G. Xu Exendin-4 protects pancreatic beta cells from human islet amyloid polypeptide-induced cell damage: potential involvement of AKT and mitochondria biogenesis Diabetes Obes Metab 12 2010 815 824
24. R.J. Armstrong, and R.A. Barker Neurodegeneration: a failure of neuroregeneration? Lancet 358 2001 1174 1176
25. G. Esposito, C.F. Ana, and P. Verstreken Synaptic vesicle trafficking and Parkinson's disease Dev Neurobiol 72 2012 134 144
26. E. Belluzzi, E. Greggio, and G. Piccoli Presynaptic dysfunction in Parkinson's disease: a focus on LRRK2 Biochem Soc Trans 40 2012 1111 1116
27. T. Kitada, A. Pisani, M. Karouani, M. Haburcak, G. Martella, and A. Tscherter et al. Impaired dopamine release and synaptic plasticity in the striatum of parkin-/- mice J Neurochem 110 2009 613 621
28. T. Kitada, A. Pisani, D.R. Porter, H. Yamaguchi, A. Tscherter, and G. Martella et al. Impaired dopamine release and synaptic plasticity in the striatum of PINK1-deficient mice Proc Natl Acad Sci U S A 104 2007 11441 11446
29. P.L. McClean, V.A. Gault, P. Harriott, and C. Holscher Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease Eur J Pharmacol 630 2010 158 162
30. A. Harkavyi, A. Abuirmeileh, R. Lever, A.E. Kingsbury, C.S. Biggs, and P.S. Whitton Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease J Neuroinflammation 5 2008 19
31. N. Rampersaud, A. Harkavyi, G. Giordano, R. Lever, J. Whitton, and P.S. Whitton Exendin-4 reverses biochemical and behavioral deficits in a pre-motor rodent model of Parkinson's disease with combined noradrenergic and serotonergic lesions Neuropeptides 46 2012 183 193
32. G. Bertilsson, C. Patrone, O. Zachrisson, A. Andersson, K. Dannaeus, and J. Heidrich et al. Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease J Neurosci Res 86 2008 326 338
33. Y. Li, T. Perry, M.S. Kindy, B.K. Harvey, D. Tweedie, and H.W. Holloway et al. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism Proc Natl Acad Sci U S A 106 2009 1285 1290
34. I. Aviles-Olmos, P. Limousin, A. Lees, and T. Foltynie Parkinson's disease, insulin resistance and novel routes to neuroprotection Brain 136 2012 374 384
35. T. Perry, D.K. Lahiri, K. Sambamurti, D. Chen, M.P. Mattson, and J.M. Egan et al. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron J Neurosci Res 72 2003 603 612
36. M.J. During, L. Cao, D.S. Zuzga, J.S. Francis, H.L. Fitzsimons, and X. Jiao et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection Nat Med 9 2003 1173 1179
37. T.A. Perry, and N.H. Greig A new Alzheimer's disease interventive strategy: GLP-1 Curr Drug Targets 5 2004 565 571
38. M.P. Mattson, T. Perry, and N.H. Greig Learning from the gut Nat Med 9 2003 1113 1115
39. C. Alves, F. Batel-Marques, and A.F. Macedo A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer Diabetes Res Clin Pract 98 2012 271 284
40. M. Wenten, J.A. Gaebler, M. Hussein, E.M. Pelletier, D.B. Smith, and P. Girase et al. Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study Diabetes Med 29 2012 1412 1418
41. M. Elashoff, A.V. Matveyenko, B. Gier, R. Elashoff, and P.C. Butler Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies Gastroenterology 141 2011 150 156
42. S. Singh, H.Y. Chang, T.M. Richards, J.P. Weiner, J.M. Clark, and J.B. Segal Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study JAMA Intern Med 173 2013 534 539
43. P.C. Butler, M. Elashoff, R. Elashoff, and E.A. Gale A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe? Diabetes Care 36 2013 2118 2125
44. M.A. Nauck A critical analysis of the clinical use of incretin-based therapies: the benefits by far outweigh the potential risks Diabetes Care 36 2013 2126 2132
45. F. Calara, K. Taylor, J. Han, E. Zabala, E.M. Carr, and M. Wintle et al. A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4) Clin Ther 27 2005 210 215
46. A.J. Kastin, and V. Akerstrom Entry of exendin-4 into brain is rapid but may be limited at high doses Int J Obes Rel Metab Disord 27 2003 313 318
47. W.A. Banks, M.J. During, and M.L. Niehoff Brain uptake of the glucagon-like peptide-1 antagonist exendin(9-39) after intranasal administration J Pharmacol Exp Ther 309 2004 469 475
48. K. Hunter, and C. Holscher Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis BMC Neurosci 13 2012 33
49. K. Iwamoto, R. Nasu, A. Yamamura, P.A. Kothare, K. Mace, and A.M. Wolka et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once weekly in Japanese patients with type 2 diabetes Endocr J 56 2009 951 962
50. I. Aviles-Olmos, J. Dickson, Z. Kefalopoulou, A. Djamshidian, P. Ell, and T. Soderlund et al. Exenatide and the treatment of patients with Parkinson's disease J Clin Invest 123 2013 2730 2736
51. Parkinson's Disease Study Group DATATOP: a multicenter controlled clinical trial in early Parkinson's disease: Parkinson Study Group Arch Neurol 46 1989 1052 1060
52. C.W. Olanow, A.H. Schapira, P.A. LeWitt, K. Kieburtz, D. Sauer, and G. Olivieri et al. TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial Lancet Neurol 5 2006 1013 1020
53. C.D. Ward Does selegiline delay progression of Parkinson's disease? A critical re-evaluation of the DATATOP study J Neurol Neurosurg Psychiatry 57 1994 217 220
54. CW Olanow, RA Hauser, J Jankovic, W Langston, A Lang, and W Poewe et al. A randomized double-blindplacebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study) rationale, design, and baseline characteristics Mov Disord 23 2008 2194 2201
55. J.E. Ahlskog, and R.J. Uitti Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction? Neurology 74 2010 1143 1148
56. C.W. Olanow, and O. Rascol The delayed-start study in Parkinson disease: can't satisfy everyone Neurology 74 2010 1149 1150
57. NET-PD LS-1 Creatine in Parkinson's Disease. A Multicenter, Double-Blind, Parallel Group, Placebo Controlled Study of Creatine in Subjects With Treated Parkinson's Disease (PD) Long Term Study (LS-1). Available at: http://clinicaltrials.gov/ct2/show/NCT00449865. Accessed February 2, 2014.
58. J.G. Nutt, K.J. Burchiel, C.L. Comella, J. Jankovic, A.E. Lang, and E.R. Laws Jr. et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD Neurology 60 2003 69 73
59. A.E. Lang, S. Gill, N.K. Patel, A. Lozano, J.G. Nutt, and R. Penn et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease Ann Neurol 59 2006 459 466
60. T. Simuni, E. Borushko, M.J. Avram, S. Miskevics, A. Martel, and C. Zadikoff et al. Tolerability of isradipine in early Parkinson's disease: a pilot dose escalation study Mov Disord 25 2010 2863 2866
61. C.G. Goetz, B.C. Tilley, S.R. Shaftman, G.T. Stebbins, S. Fahn, and P. Martinez-Martin et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results Mov Disord 23 2008 2129 2170
62. C.G. Goetz, G.T. Stebbins, and B.C. Tilley Calibration of Unified Parkinson's Disease Rating Scale scores to Movement Disorders Society-Unified Parkinson's Disease Rating Scale scores Mov Disord 27 2012 1239 1242
63. A.L. Whone, R.L. Watts, A.J. Stoessl, M. Davis, S. Reske, and C. Nahmias et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study Ann Neurol 54 2003 93 101
64. Parkinson Study Group Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression JAMA 287 2002 1653 1661